Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.
In Hodgkin's disease, Hodgkin and Reed-Sternberg cells consistently express the antigen CD30. We investigated the possible therapeutic role of an immunotoxin prepared by covalent linking of an anti-CD30 monoclonal antibody (Ber-H2) to saporin (SO6), a type-1 ribosome-inactivating protein. The immunotoxin (0.8 mg/kg in one or two doses) was given to four patients with advanced refractory Hodgkin's disease. In three, there was rapid and substantial reduction in tumour mass (50% to greater than 75%). Clinical responses were transient (6-10 weeks). In-vivo binding of the immunotoxin to tumour cells was shown by immunohistology in two patients. Antibodies to both parts of the immunotoxin developed in all patients.
Institute of Haematology, University of Perugia, Italy.
B
B
Falini
A
A
Bolognesi
L
L
Flenghi
P L
PL
Tazzari
M K
MK
Broe
H
H
Stein
H
H
Dürkop
F
F
Aversa
P
P
Corneli
G
G
Pizzolo
D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000276:immunology*; D000972:Antineoplastic Agents, Phytogenic; D006689:Hodgkin Disease / Q000473:pathology / Q000628:therapy*; D006801:Humans; D000922:Immunotoxins / Q000009:adverse effects / Q000627:therapeutic use*; D017730:Ki-1 Antigen; D009699:N-Glycosyl Hydrolases; D010940:Plant Proteins; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000972:Antineoplastic Agents, Phytogenic; D000922:Immunotoxins; D017730:Ki-1 Antigen; D010940:Plant Proteins; D054789:Ribosome Inactivating Proteins, Type 1; D009699:N-Glycosyl Hydrolases; D000076985:Saporins